Celldex Therapeutics (NASDAQ:CLDX) Rating Reiterated by Cantor Fitzgerald

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports. They presently have a $67.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 54.66% from the stock’s previous close.

A number of other research firms have also recently issued reports on CLDX. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Monday, August 12th. Wolfe Research started coverage on Celldex Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating and a $51.00 price objective for the company. Stifel Nicolaus initiated coverage on Celldex Therapeutics in a research note on Tuesday, June 18th. They issued a “buy” rating and a $58.00 target price on the stock. Finally, Wells Fargo & Company raised their target price on Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $63.83.

Celldex Therapeutics Stock Down 1.0 %

Celldex Therapeutics stock traded down $0.44 during trading hours on Monday, hitting $43.32. The stock had a trading volume of 218,621 shares, compared to its average volume of 771,130. Celldex Therapeutics has a fifty-two week low of $22.11 and a fifty-two week high of $53.18. The company has a market cap of $2.87 billion, a PE ratio of -15.20 and a beta of 1.56. The company has a 50-day moving average of $37.57 and a two-hundred day moving average of $38.97.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The company had revenue of $2.50 million for the quarter, compared to the consensus estimate of $1.13 million. As a group, analysts forecast that Celldex Therapeutics will post -2.5 EPS for the current fiscal year.

Insider Activity at Celldex Therapeutics

In other Celldex Therapeutics news, CFO Samuel Bates Martin sold 17,172 shares of Celldex Therapeutics stock in a transaction on Friday, June 14th. The shares were sold at an average price of $35.42, for a total value of $608,232.24. Following the sale, the chief financial officer now directly owns 28,125 shares in the company, valued at approximately $996,187.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Samuel Bates Martin sold 17,172 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $35.42, for a total value of $608,232.24. Following the sale, the chief financial officer now directly owns 28,125 shares of the company’s stock, valued at $996,187.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Elizabeth Crowley sold 30,000 shares of Celldex Therapeutics stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $34.87, for a total transaction of $1,046,100.00. Following the sale, the vice president now directly owns 9,074 shares in the company, valued at $316,410.38. The disclosure for this sale can be found here. 3.80% of the stock is owned by insiders.

Institutional Trading of Celldex Therapeutics

Hedge funds have recently modified their holdings of the stock. Teachers Retirement System of The State of Kentucky increased its holdings in Celldex Therapeutics by 32.0% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 40,558 shares of the biopharmaceutical company’s stock worth $1,501,000 after purchasing an additional 9,829 shares in the last quarter. Novo Holdings A S purchased a new position in shares of Celldex Therapeutics during the second quarter valued at approximately $31,458,000. Algert Global LLC grew its holdings in Celldex Therapeutics by 75.6% during the second quarter. Algert Global LLC now owns 75,614 shares of the biopharmaceutical company’s stock worth $2,798,000 after buying an additional 32,564 shares in the last quarter. D. E. Shaw & Co. Inc. raised its position in Celldex Therapeutics by 47.5% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 845,560 shares of the biopharmaceutical company’s stock valued at $31,294,000 after buying an additional 272,389 shares during the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 1,504 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.